The Patent Finder
ME

MedImmune, LLC

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as MedImmune Vaccines, Inc. (to 2008)

213 patents currently held

60 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2027. from the record

Of the 60 now held by other companies, 9 name Humabs Biomed S.A. as their current owner, and 51 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
21
Ending by 2030
Jan 2027
Next term end
128
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Targeted Binding Agents Against B7-H1 US 8,779,108
The most cited patent in this portfolio, cited by 166 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2030.
Ends Nov 2030 · High confidence
Also notable
Methods of Treatment with Antagonists Against PD-1 and PD-L1 in Combination with Radiation Therapy US 10,092,645
Cited by 20 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Ends Jun 2035 · High confidence
Also notable
Binding Molecules Specific for CD73 and Uses Thereof US 9,938,356
Cited by 23 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Ends Nov 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 5 fees due Jan 2 to 18, 2027 · next Jan 2
  • 2 fees due Feb 6 to 28, 2027 · next Feb 6
  • 4 fees due Mar 1 to 26, 2027 · next Mar 1
  • 8 fees due Apr 3 to 29, 2027 · next Apr 3
  • 5 fees due May 3 to 28, 2027 · next May 3
  • 5 fees due Jun 15 to 30, 2027 · next Jun 15
  • 2 fees due Jul 14 to 28, 2027 · next Jul 14
  • 6 fees due Aug 9 to 27, 2027 · next Aug 9
  • 5 fees due Sep 3 to 26, 2027 · next Sep 3
  • 2 fees due Oct 30, 2027
  • 2 fees due Nov 12 to 19, 2027 · next Nov 12

Which patents, and when each one lapses · Pro

Recent changes

  • Nov 9Assignment recorded on 1 record: AstraZeneca UK Limited to MedImmune Limited Recorded Nov 9, 2026, executed Jul 30, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76692, frame 866.
  • Nov 9Assignment recorded on 1 record: Reid, Fred and 2 others to MedImmune Limited Recorded Nov 9, 2026, executed Jul 30, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76692, frame 869.
  • 7 of the patents on this record were granted since Aug 23, 2026
  • 7 terms have ended since Aug 23, 2026

What they patent

The largest of its 128 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,670,837Non-Tumorigenic MDCK Cell Line for Propagating Viruses
In force
 · High confidence
In forceHigh confidence
US 8,846,032MDCK Cell Lines Supporting Viral Growth to High Titers and Bioreactor Process Using the Same
In force
 · High confidence
In forceHigh confidence
US 9,005,620Compounds
In force
 · Medium confidence
In forceMedium confidence
US 8,008,443Modulation of Antibody Effector Function by Hinge Domain Engineering
In force
 · High confidence
In forceHigh confidence
US 8,666,778Systems and Methods for Processing Requests for Pharmaceuticals That Require Insurer Preapproval
In force
 · Medium confidence
In forceMedium confidence
US 7,790,655Cell Display of Antibody Libraries
In force
 · High confidence
In forceHigh confidence
US 7,790,434Methods and Compositions for Expressing Negative-Sense Viral RNA in Canine Cells
In force
 · High confidence
In forceHigh confidence
US 9,176,129Protein Scaffolds
In force
 · High confidence
In forceHigh confidence
US 8,137,670Method of Identifying Membrane Ige Specific Antibodies and Use Thereof for Targeting Ige Producing Precursor Cells
In force
 · High confidence
In forceHigh confidence
US 9,193,789Anti-Icos Antibodies and Their Use in Treatment of Oncology, Transplantation and Autoimmune Disease
In force
 · Medium confidence
In forceMedium confidence
10 of 213 patents shown.
Pro members see all 213.
Pro members: see all 213 patents
Also on record, not counted in the 213: 60 patents in force now held by others · 218 patents ended · 145 applications pending · 371 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited